Oncolytics Biotech (ONC) News Today C$1.19 -0.12 (-9.16%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period USA News Group: Oncology Advancements Accelerate Amid Rising Early-Onset Cancer DiagnosesDecember 20 at 1:36 PM | finanznachrichten.deOncolytics Biotech Unveils Promising Cancer Therapy ResultsDecember 19 at 8:45 PM | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What HappenedOncolytics Biotech (TSE:ONC) Trading Up 14.5% - Here's What HappenedDecember 19 at 3:44 PM | marketbeat.comOncolytics Biotech (TSE:ONC) Sets New 12-Month Low - What's Next?Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low - Here's WhyDecember 16, 2024 | marketbeat.comOncolytics: DSMB recommended continued enrollment in Cohort 5 of GOBLET studyDecember 4, 2024 | markets.businessinsider.comOncolytics Biotech Progresses with GOBLET Cancer TrialDecember 4, 2024 | markets.businessinsider.comBiotech Advances Drive Cancer Research as Global Rates Continue Upward TrendDecember 2, 2024 | baystreet.caReplimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail UpbeatNovember 22, 2024 | msn.comFY2024 EPS Estimates for TSE:ONC Lowered by AnalystOncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for Oncolytics Biotech in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($0.42) per share forNovember 18, 2024 | marketbeat.comFY2024 EPS Estimates for TSE:ONC Cut by HC WainwrightOncolytics Biotech Inc. (TSE:ONC - Free Report) - Equities research analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company willNovember 18, 2024 | marketbeat.comLeede Financial Comments on TSE:ONC FY2024 EarningsOncolytics Biotech Inc. (TSE:ONC - Free Report) - Research analysts at Leede Financial issued their FY2024 earnings per share estimates for shares of Oncolytics Biotech in a report released on Wednesday, November 13th. Leede Financial analyst D. Loe anticipates that the company will post earningsNovember 18, 2024 | marketbeat.comRaymond James Upgrades Oncolytics Biotech (TSE:ONC) to "Moderate Buy"Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a report on Thursday.November 16, 2024 | marketbeat.comHC Wainwright Brokers Raise Earnings Estimates for TSE:ONCOncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at HC Wainwright upped their FY2028 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings pNovember 15, 2024 | marketbeat.comWhat is Raymond James' Forecast for TSE:ONC FY2024 Earnings?Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Investment analysts at Raymond James lowered their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings peNovember 15, 2024 | marketbeat.comBiotech Companies’ Q3 Updates: Promising Cancer Treatments on the HorizonNovember 14, 2024 | baystreet.caOncolytics Biotech (ONCY) Gets a Buy from RBC CapitalNovember 14, 2024 | markets.businessinsider.comOncolytics Biotech: Innovative Cancer Treatment Advancements Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comOncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 13, 2024 | finance.yahoo.comOncolytics Biotech Announces Q3 Results ConferenceNovember 11, 2024 | markets.businessinsider.comEarnings Preview: Oncolytics BiotechNovember 11, 2024 | benzinga.com10 cheap healthcare stocks to buy nowNovember 11, 2024 | msn.comOncolytics Biotech (TSE:ONC) Shares Pass Above 200-Day Moving Average - Here's WhyOncolytics Biotech (TSE:ONC) Share Price Passes Above 200-Day Moving Average - What's Next?November 9, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Shares Pass Above 200-Day Moving Average - Should You Sell?Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200-Day Moving Average - What's Next?November 1, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Shares Pass Above 200-Day Moving Average - What's Next?Oncolytics Biotech (TSE:ONC) Shares Cross Above 200 Day Moving Average - Time to Sell?October 24, 2024 | marketbeat.comOncolytics targets accelerated approval for oncolytic virus therapyOctober 18, 2024 | msn.comOncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200-Day Moving Average - What's Next?Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200 Day Moving Average - Here's What HappenedOctober 16, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Trading Down 7.9% - Should You Sell?Oncolytics Biotech (TSE:ONC) Shares Down 7.9% - What's Next?October 8, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Stock Price Up 11.8% - Should You Buy?Oncolytics Biotech (TSE:ONC) Trading 11.8% Higher - Should You Buy?October 4, 2024 | marketbeat.comFDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%October 4, 2024 | baystreet.caBuzz on the Bullboards: TSX stocks making headlines this weekSeptember 26, 2024 | msn.comTransgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025September 24, 2024 | finance.yahoo.comBuy Rating Affirmed for Oncolytics Biotech on Strong Phase 2 Results and Commercial PotentialSeptember 20, 2024 | markets.businessinsider.comOncolytics Biotech (TSE:ONC) Given New C$3.50 Price Target at Raymond JamesRaymond James boosted their price objective on shares of Oncolytics Biotech from C$3.00 to C$3.50 in a report on Friday.September 20, 2024 | marketbeat.comBuy Rating Justified by Promising Pelareorep Outcomes in mBC Treatment and Anticipated Shareholder ValueSeptember 20, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Oncolytics Biotech Inc. Cut by HC Wainwright (TSE:ONC)Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Oncolytics Biotech in a research note issued on Wednesday, August 21st. HC Wainwright analyst P. Trucchio now expects that the company will earn ($August 23, 2024 | marketbeat.comBuy Rating Affirmed for Oncolytics Biotech with Promising Developments in Cancer Therapy TrialsAugust 22, 2024 | markets.businessinsider.comExtending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast CancerAugust 17, 2024 | theglobeandmail.comSernova Names Jonathan Rigby as New CEOAugust 12, 2024 | marketwatch.comEarnings call: Oncolytics Biotech outlines progress in cancer trialsAugust 4, 2024 | investing.comOncolytics Biotech (TSE:ONC) Stock Passes Above Two Hundred Day Moving Average of $1.47Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200 Day Moving Average of $1.47August 2, 2024 | marketbeat.comIntegrated Cyber Solutions IncJuly 26, 2024 | baystreet.caOncolytics Biotech (ONC) Set to Announce Earnings on ThursdayOncolytics Biotech (TSE:ONC) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.July 25, 2024 | marketbeat.comClosing Bell: Oncolytics Bio flat on Tuesday (ONC)July 24, 2024 | theglobeandmail.comBioInvent International: BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMOJuly 23, 2024 | finanznachrichten.deOncolytics Biotech (TSE:ONC) Stock Price Passes Above 200 Day Moving Average of $1.49Oncolytics Biotech (TSE:ONC) Share Price Crosses Above Two Hundred Day Moving Average of $1.49July 17, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Share Price Passes Below Two Hundred Day Moving Average of $1.50Oncolytics Biotech (TSE:ONC) Stock Price Passes Below 200 Day Moving Average of $1.50July 9, 2024 | marketbeat.comOncolytics Biotech (TSE:ONC) Shares Cross Below 200-Day Moving Average of $1.57Oncolytics Biotech (TSE:ONC) Stock Passes Below 200-Day Moving Average of $1.57June 11, 2024 | marketbeat.comFY2024 Earnings Forecast for Oncolytics Biotech Inc. (TSE:ONC) Issued By HC WainwrightOncolytics Biotech Inc. (TSE:ONC - Free Report) - Research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Oncolytics Biotech in a research note issued on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.38) per sharMay 16, 2024 | marketbeat.comHC Wainwright Weighs in on Oncolytics Biotech Inc.'s FY2028 Earnings (TSE:ONC)Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Equities research analysts at HC Wainwright dropped their FY2028 EPS estimates for Oncolytics Biotech in a report issued on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.58 per share for the year, dMay 15, 2024 | marketbeat.comOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer TrialMay 15, 2024 | finance.yahoo.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. ONC Media Mentions By Week ONC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONC News Sentiment▼-0.480.60▲Average Medical News Sentiment ONC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONC Articles This Week▼41▲ONC Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fennec Pharmaceuticals News Medicenna Therapeutics News Theratechnologies News Covalon Technologies News Sernova News Microbix Biosystems News Aeterna Zentaris News Resverlogix News Sirona Biochem News Kane Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:ONC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
